Global Premier CRDMO: Enabling Global Partners and Delivering Sustainable High Growth

Chris Chen PhD

41st Annual J.P. Morgan Healthcare Conference

January 11, 2023

WuXi Biologics

Global Solution Provider

Stock Code: 2269.HK
Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

We have provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
CONTENTS

01 Business Update

02 Summary of Company’s Performance Post IPO

03 ESG as an Important Component of Business Strategy

04 Summary
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

- WuXi Biologics will provide an exclusive license to GSK for 1 preclinical bispecific T cell engaging (TCE) antibody and 3 additional bi-/multi-specific TCE antibodies developed using WuXi Biologics’ proprietary technology platforms.

- WuXi Biologics will receive an upfront payment of US$40 million, up to ~US$1.4 billion at key milestones and tiered royalties on net sales.

Multiple-Platform Discovery Engines

- Goal of WuXi Biologics is to develop exceptional technology platforms to serve global clients.

- Low-toxicity CD3, WuXiBody® and SDArBody™ bi-/multi-specific technologies: potential best in class for cancer therapeutics.

- This deal fully validates our business model.

- A clear demonstration of CRDMO: 4 potential subsequent development and commercial mfg programs.
Business continues to accelerate despite biotech funding slowdown, UVL and COVID in China

136 new integrated projects added as of Dec. 31, 2022 vs 120 targeted

“Win-the-Molecule” Strategy continued to excel: 11 external projects transferred into the pipeline as of Dec. 31, 2022, including 5 phase III/Commercial projects to boost near-term revenue and secure long-term manufacturing contracts

17 commercial projects as of Dec. 31, 2022, accelerating business momentum to fuel the future growth

These numbers show that UVL challenges did not impede growth
### “Win-the-Molecule” Strategy: New Driver to Expand Pipeline and Deliver Additional Near-term Growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>2019</td>
<td>1</td>
<td>11</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>2020</td>
<td>1</td>
<td>4</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>2021</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>18</td>
</tr>
<tr>
<td>2022</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>11</td>
</tr>
</tbody>
</table>

- Total **51** projects at different stages (Phase I, II and III + CMO) transferred from global CDMOs or large pharmas to WuXi Biologics since 2018: **20** phase III & CMO projects will drive significant near-term growth.
- Excellent execution, best timeline and leading technology underpin “Win-the-Molecule” strategy.
Banner Year for Commercial Manufacturing: from 2021 and Beyond

2020 CMO Prediction

1H2022 CMO Prediction

2023 CMO Prediction

- CMO projects are expected to increase by implementing “Follow & Win the Molecule” strategies
- “Win-the-molecule” enables WuXi Bio to secure more potential CMO projects
Explosive Growth of Commercial Projects in the Near Term

**Five** manufacturing projects that could potentially generate US$200 mm+ peak revenue per year
- Cancer bispecific A
- Cancer bispecific B
- FcRn mAb
- TIGIT mAb
- Cancer ADC Z

**Eight** manufacturing projects that could potentially generate US$100-200 mm peak revenue per year
- Pompe ERT
- Cancer mAb
- Cancer bispecific C
- Non-COVID Vaccine
- Global biosimilar 1
- Global biosimilar 2
- Global biosimilar 3
- Infectious disease mAb1

**Eight** manufacturing projects that could potentially generate US$50-100 mm peak revenue per year
- Cancer bispecific D
- Cancer ADC Y
- CD38 mAb
- DR5 mAb
- Global biosimilar 4
- Cancer ADC X
- Gaucher’s disease ERT
- Infectious disease mAb 2

- Multiple programs and higher POS for exciting targets, signed 4 exclusive CMO deals (dual sourcing within WuXi Biologics)
- Inventory-built for biologics can start 2-3 years before approval due to complexity of manufacturing and long supply chain
- CMO revenue from these projects expected to be US$2+ bn
## Excellent Operational Metrics

### 2022 R&D Track Records

- Enabled **100+** INDs in 2022 including **1st** RNA IND
- Delivered more than **2,000Kg** of COVID mAbs
- Developed **90+** cell based assays in 2022 and developed **300+** in total since 2017
- Completed **70+** GMP audits/inspections in 2022. **400+** audits/inspections completed since 2013
- Published **10** papers on bispecific purification, **38** publications in total
- Received EMA GMP certificate **10 months** after facility release
- **5,188** proteins generated to support global research
- **1,000** viral clearance projects completed since 2013

### MFG Operational Excellence

- **DS:** **11** PPQ campaigns at **100%** success rate in 2022 and **2,100+** batches completed at **99%+** success rate overall
- **DP:** **8** PPQ campaigns completed at **100%** success rate in 2022 and **1,400+** batches completed at **99%** success rate overall, **100%** mfg success for three years in a row
- **100** batches completed under 12,000L MFG line at **98%** success rate
- **15** facilities with **~262,000L** DS capacity in 2022 vs **~580,000L** after 2026
- **11** facilities for drug product filling, including **1** bioconjugate DP in 2022
- Building **13** facilities globally
QUALITY is Our Competitive Advantage and Moat

Number of Regulatory Inspections: 27

Number of License Approvals: 37

Number of Certified Facilities: 14

Note:
1. As of Dec 31, 2022
## M&As Proven to Be Successful

<table>
<thead>
<tr>
<th>Seller</th>
<th>Bayer Leverkusen</th>
<th>Bayer Wuppertal</th>
<th>Pfizer China Hangzhou</th>
<th>CMAB Suzhou</th>
</tr>
</thead>
<tbody>
<tr>
<td>Close Date</td>
<td>April 2020</td>
<td>1H 2021</td>
<td>1H 2021</td>
<td>1H 2021</td>
</tr>
<tr>
<td>Capacity</td>
<td>10 mm vials/year</td>
<td>2 lines (15,000L)</td>
<td>1 line (4,000L), 5 mm vials, 2 mm PFS/year</td>
<td>4 lines (7,000L), 2 mm vials/year</td>
</tr>
</tbody>
</table>

### Synergy

- **First** German facilities including DS and DP
- Meet growing demands worldwide
- Strengthen “Global Dual Sourcing” strategy
- Access to state of art DS/DP facility and experienced workforce
- Immediately ease manufacturing bottleneck in DS and DP
- Adding new capacity in 2021 to gain more market share
- Strengthen market leadership with integrated offerings to enable more customers

### Key Points

- **M&A of assets:** typically **60-70%** discount, higher ROI than internal-build
- **M&A deals are expected to contribute** **US$200+ mm** revenue in the first 12 months of operations and earning accretive (due to global shortage of DS and DP capacities)
WuXi Biologics (Suzhou): Production Volume Increases 4X in 2 years with 100% Success Rate

- Production capability increased to 100+ batches per year
- 90 batches delivered in 2022
- 100% success rate so far

- Production capability increased to 60+ batches per year
- 60 batches delivered in 2022
- Improved the success rate from ~70% to 100%
- Facility utilization rate >80%
Execution at Suzhou (What We Can Achieve in Just 1 Year)
Revenue Increased 3X, GP Margin ~50% Expected

<table>
<thead>
<tr>
<th>Metric</th>
<th>2021 (X) to 2022 (Y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Number</td>
<td>2021 (14) to 2022 Q3 (95)</td>
</tr>
<tr>
<td>Revenue / HC</td>
<td>MFG21: 2021 (0.25) to 2022E (0.59)</td>
</tr>
<tr>
<td></td>
<td>DP11: 2021(0.07) to 2022E (0.23)</td>
</tr>
<tr>
<td>Deviation / Batch</td>
<td>MFG21: 2021 (1.4) to 2022C (0.88)</td>
</tr>
<tr>
<td></td>
<td>DP11: 2021 (0.77) to 2022C (0.23)</td>
</tr>
<tr>
<td>MFG21 Capacity</td>
<td>300%</td>
</tr>
<tr>
<td>DP11 Capacity</td>
<td>500%</td>
</tr>
<tr>
<td>Batch / HC</td>
<td>MFG21: 2021 (0.35) to 2022E (0.45)</td>
</tr>
<tr>
<td></td>
<td>DP11: 2021(1.23) to 2022E (1.47)</td>
</tr>
<tr>
<td>Major Findings / Audit</td>
<td>2021 (6.9) to 2022C (0.11)</td>
</tr>
<tr>
<td></td>
<td>DP11 2021 Q3 (2.0) to 2022C (0.16)</td>
</tr>
</tbody>
</table>
From a new Facility to World-class CRDMO Operations in 12 Months – WuXi Biologics Hangzhou

2022 Numbers
- DP 40 Batches (80% design capacity)
- DS 35 Batches (1.5x design capacity)
- 100% SUCCESS with 50%+ GP

2021
- May 1: Day 1 of the acquisition
- June 2: Completion of the first DP run
- June 25: HC increased to 300
- July 1: 1st DS Vial Thaw
- July 25: Completion of first DS PPQ
- Oct. 9: 2x2,000L XDR released

2022
- Jan 5: HC increased to 300
- May 26: DP9 Modification completed
- Oct. 9: 2x2,000L XDR released
- June 20: Kick off 15000L expansion

Stage1: Initial Capacity
- June 2: Completion of the first DP run
- 106 People, 2x2,000L

Stage2: Continuous Improvement
- October 22: Completion of first Covid-19 fusion protein production
- 300 People

Stage3: Lean Operations
- May 26: DP9 Modification completed
- June 20: Kick off 15000L expansion
- 432 People, 4x2,000L

2022 Numbers
- DP 40 Batches (80% design capacity)
- DS 35 Batches (1.5x design capacity)
- 100% SUCCESS with 50%+ GP
Robust Global Network to Enable Partners: Multiple Nodes with Geographic Diversity

Global CRDMO: 2 R centers + 8 D centers + 9 M centers

R: Shanghai WGQ, Shanghai FX

D: Shanghai WGQ, Wuxi, Shanghai FX, Chengdu, Hangzhou, Suzhou, Cranbury NJ and Singapore

M: Wuxi, Hebei, Chengdu, Hangzhou, Wuppertal, Leverkusen, Dundalk, Worcester MA and Singapore
New Chapter for Global Operations: Full Supply Chain from DNA to BLA in US&EU

- MFG18, the first clinical manufacturing facility in U.S., started GMP operations in mid 2022
  - Hosted 19 client visits and signed US$54 mm contracts 1H 2022
  - Attracted 10+ new clients to WuXi Bio

- Construction on track and completed building steel work in Oct. 2022, GMP operation targeted in 2024
  - Another choice in the U.S. within WuXi Bio global network

- MFG6/7 in Ireland is GMP release in Q4 2022, and received first GMP Certificate from Ireland Health Products Regulatory Authority
  - Initiate the preparation work of 4 manufacturing projects
  - 5+ Win-the-Molecule large scale manufacturing projects in discussions

- MFG8 in Hebei, China: a 48,000L commercial DS manufacturing facility is GMP release in Oct.
  - 12x4,000L single-use bioreactor
  - A showcase of best practices for the “Factory of the Future”

MFG18 in New Jersey, U.S.
MFG11 in Massachusetts, U.S.
MFG6/7 in Dundalk, Ireland
MFG8 in Hebei, China
Successful Delisting from UVL: Demonstration of Global Standards and Compliance

Added to UVL
- Two subsidiaries – Wuxi and Shanghai – were added to UVL
- Communicated with all clients to address concerns

End-Use Check Completed at Wuxi site
- End-use check for Wuxi site completed in June

End-Use Check Completed at Shanghai site
- End-use check for Shanghai site completed in late October

No Business Impact or Supply Chain Disruption
- Signed two US$100+ mm MFG contracts with two large pharma

Wuxi Site Removed from UVL
- Wuxi site was removed from UVL on Oct. 7

Shanghai Site Removed from UVL
- Shanghai site was removed from UVL on Dec. 16
Summary of Company’s Performance Post IPO
CRDMO Business Model Well Proven Since IPO

Four key numbers fully describe business of WuXi Biologics: Total Project Number, Newly Added Integrated Project per year, No. of Phase III Programs and No. of Commercial Projects

- Total project number increased by 4.7X
- Newly added projects increased by 1.7X
- Phase III projects increased by 11X
- Commercial projects increased by 16X

Built-in growth engine from the pipeline (snowballing effect): acceleration of project growth to later stage with higher revenue per project: preclinical projects 3.5X  Phase I/II 6.1X
“Follow and Win the Molecule” Strategies Driving Robust Growth

No. of Newly Added Integrated Projects

<table>
<thead>
<tr>
<th>Year</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>58</td>
<td>57</td>
<td>59</td>
<td>103</td>
<td>138</td>
<td>136</td>
</tr>
</tbody>
</table>

CAGR: +18.6%

No. of Total Integrated Projects (1)

<table>
<thead>
<tr>
<th>Year</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>103</td>
<td>161</td>
<td>205</td>
<td>250</td>
<td>334</td>
<td>480</td>
<td>588</td>
</tr>
</tbody>
</table>

CAGR: +33.7%

No. of “Win-the-Molecule” Phase III & CMO Projects (2)

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>1</td>
<td>2</td>
<td>8</td>
<td>15</td>
<td>20</td>
</tr>
</tbody>
</table>

CAGR: +111.5%

No. of “Win-the-Molecule” Projects (2)

<table>
<thead>
<tr>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>10</td>
<td>11</td>
<td>22</td>
<td>40</td>
<td>51</td>
</tr>
</tbody>
</table>

CAGR: +50.3%

Notes:
1. Integrated projects are defined as projects requiring services for multiple stages during biologics development process
2. “Win-the-Molecule” projects are shown in accumulative number
3. Newly-added integrated project number in 2021 has excluded the projects from CMAB
Sustained High Growth with Diverse Engines

2016 Revenue Distribution
- North America: 54.2%
- PRC: 39.0%
- Europe: 2.1%
- Rest of the world: 4.7%

2019 Revenue Distribution
- North America: 53.7%
- PRC: 35.3%
- Europe: 7.8%
- Rest of the world: 6.2%

1H2022 Revenue Distribution
- North America: 54.1%
- PRC: 24.9%
- Europe: 17.9%
- Rest of the world: 3.1%

Notes:
1. Customers are classified into different regions based on their headquarters.
2. Rest of the world primarily includes Singapore, Japan, South Korea, Australia and Israel.
Consistent and Robust Financial Performance in the Last Eight Years

### Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>RMB mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>331.9</td>
</tr>
<tr>
<td>2015</td>
<td>557.0</td>
</tr>
<tr>
<td>2016</td>
<td>989.0</td>
</tr>
<tr>
<td>2017</td>
<td>1,618.8</td>
</tr>
<tr>
<td>2018</td>
<td>2,534.5</td>
</tr>
<tr>
<td>2019</td>
<td>3,983.7</td>
</tr>
<tr>
<td>2020</td>
<td>5,612.4</td>
</tr>
<tr>
<td>2021</td>
<td>10,290.1</td>
</tr>
<tr>
<td>2022E</td>
<td>15,248.9</td>
</tr>
</tbody>
</table>

Revenue CAGR: +61.4%

### Adjusted Net Profit (2)

<table>
<thead>
<tr>
<th>Year</th>
<th>RMB mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>46.7</td>
</tr>
<tr>
<td>2015</td>
<td>71.4</td>
</tr>
<tr>
<td>2016</td>
<td>220.5</td>
</tr>
<tr>
<td>2017</td>
<td>432.9</td>
</tr>
<tr>
<td>2018</td>
<td>751.5</td>
</tr>
<tr>
<td>2019</td>
<td>1,201.4</td>
</tr>
<tr>
<td>2020</td>
<td>1,715.8</td>
</tr>
<tr>
<td>2021</td>
<td>3,508.6</td>
</tr>
<tr>
<td>2022E</td>
<td>4,892.7</td>
</tr>
</tbody>
</table>

Adjusted Net Profit CAGR: +78.9%

### Notes:
1. The authorized and issued shares of the Company were subdivided on the basis that every one (1) issued share is subdivided into three (3) subdivided shares (the “Share Subdivision”), which became effective on November 16, 2020. Basic and diluted earnings per share were stated after taking into account the effect of the Share Subdivision. Comparative figures have also been restated on the assumption that the Share Subdivision had been effective in the prior year.
2. Adjusted net profit excludes the share-based compensation expenses, investment gains, foreign exchange (gains)/losses and listing expenses.
3. Refer to foreign exchange (gains)/losses.
4. 2022 estimates are sourced from Bloomberg Best Mean Consensus, and the actual numbers are subject to 2022 annual results announcement.

- **61.4%** revenue CAGR 2014-2022
- **78.9%** Adjusted NP CAGR 2014-2022
- Revenue increased by **~14X** since IPO
- Adj. NP rose by **~21X** since IPO
- Adjusted Net Profit Margin increased from **14.1%** to **33.4%**
ESG as an Important Component of Business Strategy
Recognized Industry Leader in ESG Performance (Partial List)

- ESG Industry Top-rated Company 2019 - 2021
- Top 10 Constituent of FTSE4Good Emerging Index 2021- 2022
- MSCI ESG Rating of A 2019-2021
- Best ESG Award 2020 - 2022
- EcoVadis Bronze Medal 2022
- Platinum Award Winner 2021
EcoVadis is one of the largest global Sustainability Rating Platforms enabling MNCs, including top pharma companies to evaluate and enhance their supply chain sustainability.

“This is really fantastic news! So exciting to hear WuXi Biologics is doing an excellent job with EcoVadis.”

— feedback from one of our Top Pharma clients
Global Biologics CDMO Industry Continues to Grow

Global Biologics CDMO Market Size, 2017-2030E

USD bn

Source: Frost & Sullivan, September 2022

- MNCs are more willing to outsource than expand capacity due to inflation
- The surging demands of AD drugs and the constrains of global biologics capacity further drive the growth of CDMO industry
- Multiple biologics set to lose exclusivity in next few years, which may lead to the market expansion of biosimilar - another tailwind for CDMO industry

Note:
1. CGT is not included
Well Established Partnership with Global Biotech and Pharma Clients

Biotech: CDMO Partner

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>WuXi Bio</td>
<td>3%</td>
<td>41%</td>
</tr>
<tr>
<td>Peer A</td>
<td>13%</td>
<td>39%</td>
</tr>
<tr>
<td>Peer B</td>
<td>10%</td>
<td>31%</td>
</tr>
<tr>
<td>Peer C</td>
<td>13%</td>
<td>16%</td>
</tr>
<tr>
<td>Peer D</td>
<td>12%</td>
<td>10%</td>
</tr>
<tr>
<td>Peer E</td>
<td>6%</td>
<td>10%</td>
</tr>
<tr>
<td>Peer F</td>
<td>6%</td>
<td>13%</td>
</tr>
</tbody>
</table>

Source: AlphaWise, MS Research, Total Sample: 100

Pharma: CDMO Partner

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>WuXi Bio</td>
<td>10%</td>
<td>33%</td>
</tr>
<tr>
<td>Peer A</td>
<td>21%</td>
<td>51%</td>
</tr>
<tr>
<td>Peer B</td>
<td>14%</td>
<td>47%</td>
</tr>
<tr>
<td>Peer C</td>
<td>3%</td>
<td>35%</td>
</tr>
<tr>
<td>Peer D</td>
<td>14%</td>
<td>14%</td>
</tr>
<tr>
<td>Peer E</td>
<td>10%</td>
<td>24%</td>
</tr>
<tr>
<td>Peer F</td>
<td>14%</td>
<td>20%</td>
</tr>
</tbody>
</table>

Source: AlphaWise, MS Research, Total Sample: 100
Free Cash Flow Positive in 2022: Huge Milestone

- Net operating cash flow recorded ~74%
- CAGR growth from 2017 to 2022
- Free cash flow turned positive in 2022: critical milestone for company growth, no need to use equity to fund growth
- US$4+ bn USD CAPEX investment 2017-2022 to support business growth
Non-COVID Projects Driving Growth with Strong Momentum

- Despite additional contributions from COVID-19 projects, the number of non-COVID projects grew much stronger due to unique CRDMO business model, advanced R&D capabilities, excellent execution, validated quality system and proven track record.
- The revenue contribution derived from non-COVID projects increased more significantly than COVID projects, mainly driving the growth for the Company.
- With more inflow of the non-COVID projects, the visibility of the robust business momentum is high and these projects are set to be the growth engine for the Group going forward.
Proven CRDMO Business Model Continues to Deliver Sustainable High Growth

Contract Services
- Target Selection
- Reagent/Protein Generation & Assay Development
- Antibody Generation
- Complex Biologics Engineering (e.g., ADCs bsAb)
- Lead ID & Optimization
- Developability Assessment
- Characterization: (e.g., PK, PD, Efficacy, & Exploratory Tox)
- PCC Selection
- Regulatory Support

Requisites
Innovative technology platforms enable more drug discovery innovation

Current State
- Best mAb platform demonstrated by Arcus deal in 2018
- Best bispecific platform demonstrated by GSK collaboration
- 120+ new integrated projects per year

Achievements
- US$7+ bn milestone backlog and 44 programs with low single digit royalties
- ~US$1 bn revenue per year from new projects only
- 500+ programs

Best-in-class technology platforms, maximum scalability, speed and execution

Large CAPEX, Strong Quality and Execution

Best-in-class technology platforms, maximum scalability, speed and execution

Large CAPEX, Strong Quality and Execution

Current State
- Best mAb platform demonstrated by Arcus deal in 2018
- Best bispecific platform demonstrated by GSK collaboration
- 120+ new integrated projects per year

Achievements
- US$7+ bn milestone backlog and 44 programs with low single digit royalties
- ~US$1 bn revenue per year from new projects only
- 500+ programs

Strongest growth potential benefiting from feed from R&D
- “Win-the-Molecule” expedites M

One partner with expertise in all areas

- DS GMP Manufacturing
- DP GMP Manufacturing
- QC Lot Release & Stability
- Global Dual Source Support

Requisites
Innovative technology platforms enable more drug discovery innovation

Current State
- Best mAb platform demonstrated by Arcus deal in 2018
- Best bispecific platform demonstrated by GSK collaboration
- 120+ new integrated projects per year

Achievements
- US$7+ bn milestone backlog and 44 programs with low single digit royalties
- ~US$1 bn revenue per year from new projects only
- 500+ programs

Strongest growth potential benefiting from feed from R&D
- “Win-the-Molecule” expedites M

One partner with expertise in all areas

- DS GMP Manufacturing
- DP GMP Manufacturing
- QC Lot Release & Stability
- Global Dual Source Support
Despite external challenges, business and financial metrics in 2022 reached all time high: free cash flow positive, one of the best in new projects added, “win-the-molecule” projects, phase III and commercial projects.

Unique CRDMO model will continue to drive sustainable high growth: from CMO to CDMO to CRDMO, potential to enable our clients with several global blockbusters in the near term.

Count on WuXi Biologics to do the right things and do it well: M&A, invest in technology platforms for the future (additional billion dollar deal potentials).
WuXi Bio Vision

“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry.